Reata Pharmaceuticals, Inc.
-
Ticker
RETA
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 201-500 Employees
- Based in Plano, Texas
Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone methyl (“bardoxolone”) and omaveloxolone, target the important transcription factor Nrf2 that
…More promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.
REPORT RATINGS
4.8 / 5.0 (282)
Reata Pharmaceuticals, Inc. reports have an aggregate usefulness score of 4.8 based on 282 reviews.
Reata Pharmaceuticals, Inc.
Most Recent Annual Report
MOST RECENT
2022 Annual Report and Form 10K
Older/Archived Annual Reports